New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Business Wire•06/10/2026•08:00 ET
0
Key Highlights
- ➤Rectal cancer study showed Signatera detected every local growth or recurrence, with 100% sensitivity.
- ➤Rectal cancer study showed Signatera achieved 97% specificity following neoadjuvant treatment.
- ➤Anal cancer Signatera-positive patients had 8% 18-month progression-free survival after chemoradiation.
- ➤Anal cancer Signatera-negative patients had 97% 18-month progression-free survival after chemoradiation.
- ➤Vulvovaginal cancer Signatera positivity preceded every radiographic recurrence by median 117 days.
Expert Statements
Minetta Liu, M.D., Chief medical officer, oncology and early cancer detection, Natera
“Cancer management is a multidisciplinary effort that includes both local and systemic treatment.”
Minetta Liu, M.D., Chief medical officer, oncology and early cancer detection, Natera
“Radiation oncologists are on the front lines of some of the most consequential treatment decisions in cancer care, and the data presented at ASTRO support the value of including Signatera monitoring as part of the clinical toolkit.”
Minetta Liu, M.D., Chief medical officer, oncology and early cancer detection, Natera
“What excites us about these findings is not just the strength of the data, but what they signal about where this field is heading.”
Minetta Liu, M.D., Chief medical officer, oncology and early cancer detection, Natera
“We are proud to be generating the evidence to help move it there.”
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera’s role in informing personalized care management, including radiotherapy treatments
Get started
Create a free account to read the full story.